Measles is making a concerning comeback in parts of Europe, prompting health officials to renew calls for adults to check their vaccination status. Once considered a childhood illness largely under control, recent outbreaks have revealed significant gaps in immunity among grown-ups, many of whom may have missed doses or received incomplete vaccination during childhood. As clinicians in Germany and neighboring countries report rising cases, verifying measles immunity has shifted from an occasional consideration to a routine step in primary care visits.
The resurgence is not isolated. According to the European Centre for Disease Prevention and Control (ECDC), measles cases in the EU/EEA increased more than tenfold in 2023 compared to the previous year, with over 3,000 reported infections. France, Germany, and Romania have seen some of the highest numbers, prompting national health agencies to issue alerts. In Germany alone, the Robert Koch Institute (RKI) recorded 79 measles cases in the first three months of 2024 — already nearing the total for all of 2023. Health experts warn that without urgent action to close immunity gaps, sustained transmission could re-establish itself in communities where vaccination rates have dipped below the 95% threshold needed for herd protection.
Measles, caused by the measles virus, is one of the most contagious infectious diseases known. It spreads through respiratory droplets when an infected person coughs or sneezes, and the virus can remain airborne or on surfaces for up to two hours. Initial symptoms include high fever, cough, runny nose, and red, watery eyes, followed by a characteristic red rash that typically starts on the face and spreads downward. While most people recover, complications can be severe — especially in young children, pregnant women, and those with weakened immune systems — ranging from pneumonia and encephalitis to, in rare cases, death.
Vaccination remains the most effective defense. The measles-mumps-rubella (MMR) vaccine, typically given in two doses during childhood, provides about 97% protection against measles when both doses are administered. However, many adults born between 1970 and 1990 may have received only one dose or none at all, depending on national vaccination schedules at the time. Others may lack documentation of their immunization history, making it difficult to confirm status without testing. In response, healthcare providers across Europe are now advised to routinely assess measles immunity during clinical encounters — particularly for adults planning travel, working in healthcare or education, or living in communal settings.
Why Adult Vaccination Gaps Persist
Several factors contribute to incomplete measles immunity among adults. In some European countries, the second dose of the MMR vaccine was not routinely introduced until the late 1990s or early 2000s. For example, in Germany, the Standing Committee on Vaccination (STIKO) recommended a two-dose schedule starting in 1998, meaning individuals born before then may have only received one dose. Similarly, in France, a second dose was not universally implemented until 2005. Adults in their 30s to 50s may assume they are protected when, in fact, their immunity is incomplete or has waned over time.
Vaccine hesitancy and misinformation have as well played a role, though to a lesser extent in older adult cohorts compared to younger parents making decisions for their children. Still, gaps in public awareness persist. A 2022 survey by the European Commission found that while 85% of respondents believed vaccines are important, only 65% felt well-informed about which vaccinations they personally needed as adults. This lack of awareness is compounded by the fact that, unlike childhood vaccinations, adult immunization is not systematically tracked in many national systems, leaving individuals responsible for maintaining their own records.
Travel further complicates the picture. Measles remains endemic in many parts of the world, and international travel can quickly spark outbreaks when unvaccinated or under-vaccinated individuals are exposed abroad and return home infectious. The World Health Organization (WHO) estimates that over 9 million measles cases occurred globally in 2022, with significant increases in Africa and the Eastern Mediterranean. Even brief exposure in airports, hotels, or tourist sites can pose a risk, making pre-travel vaccination checks a critical preventive step.
How Immunity Is Assessed and Confirmed
When a patient’s vaccination history is unclear, clinicians have two primary options: administer a dose of the MMR vaccine as a precaution or order a serological test to measure measles-specific immunoglobulin G (IgG) antibodies. The presence of these antibodies indicates past immunity, either from vaccination or prior infection. According to the RKI, a single dose of MMR vaccine is safe and effective for adults with uncertain status, even if they are already immune, as there is no increased risk of adverse events from additional dosing.
In practice, many German clinics now include measles immunity checks as part of routine preventive care, especially during visits for chronic disease management, prenatal care, or occupational health screenings. Some health insurance providers cover the cost of antibody testing when medically indicated, though policies vary. Public health campaigns, such as Germany’s “Impfpass kontrollieren” (Check Your Vaccination Passport) initiative, encourage adults to locate their vaccination records and consult their doctor if doses are missing.
The process is straightforward: patients are asked to bring any available vaccination documentation to their appointment. If records are absent or incomplete, a blood test can be drawn to check for measles IgG. Results typically return within a few days. If immunity is not confirmed, a single dose of MMR vaccine is offered — often during the same visit. The vaccine is generally well-tolerated, with mild side effects such as soreness at the injection site, low-grade fever, or temporary rash occurring in a small minority of recipients.
Who Should Prioritize a Measles Immunity Check?
While all adults benefit from knowing their vaccination status, certain groups are at higher risk and should consider verification a priority. Healthcare workers are at the top of the list due to their increased exposure risk and potential to transmit the virus to vulnerable patients. In Germany, occupational health guidelines strongly recommend that all medical staff have documented proof of two MMR doses or positive serology. Similar recommendations apply to teachers, childcare workers, and university students living in dormitories — settings where close contact facilitates rapid spread.
Individuals planning international travel, especially to regions with ongoing measles transmission, should review their vaccination status at least four to six weeks before departure. The CDC and ECDC advise that anyone without evidence of immunity receive an MMR dose prior to travel, regardless of age. Pregnant women or those planning pregnancy should also verify immunity, as measles infection during pregnancy increases the risk of preterm labor, low birth weight, and maternal complications — though the MMR vaccine itself is not recommended during pregnancy and should be administered before conception or after delivery.
Adults with weakened immune systems due to conditions like HIV, cancer, or immunosuppressive therapy require special consideration. While they may not be able to receive the live attenuated MMR vaccine, knowing their immunity status helps guide protective measures, such as avoiding exposure during outbreaks or considering immunoglobulin prophylaxis in high-risk scenarios. These decisions are best made in consultation with a specialist familiar with the patient’s medical history.
Public Health Response and Outreach Efforts
National health agencies are responding to the measles resurgence with targeted outreach. In Germany, the RKI has updated its online vaccination checklist to include specific prompts for adults to review their MMR status. The agency also collaborates with medical associations to distribute guidelines encouraging physicians to discuss vaccination during routine visits. In France, Santé publique France launched a regional awareness campaign in 2023 focusing on young adults in urban areas where vaccination rates have historically lagged.
At the European level, the ECDC supports cross-border coordination through the European Vaccination Information Portal, which provides country-specific schedules and resources. The WHO’s European Region has set a goal of eliminating measles and rubella by achieving and sustaining at least 95% coverage with two doses of MMR vaccine across all countries. While progress has been made, recent setbacks highlight the fragility of elimination status when immunity gaps persist.
Digital tools are also playing a role. Several countries now offer electronic vaccination records accessible through national health apps or online portals. In Germany, the Impfpass is increasingly available in digital form via the Corona-Warn-App’s successor infrastructure, allowing users to store and share immunization data securely. These systems aim to reduce reliance on paper records and make it easier for individuals to stay up to date.
What In other words for Patients and Providers
For patients, the message is clear: assuming immunity based on childhood vaccination alone can be risky. A simple conversation with a healthcare provider — supported by a record check or blood test when needed — can confirm protection or provide an opportunity to catch up safely. There is no downside to verifying status, and the peace of mind that comes with confirmed immunity is valuable, especially amid rising case numbers.
For providers, integrating measles immunity checks into standard practice aligns with preventive care principles. It requires minimal time but offers significant protection, not just for the individual patient but for the broader community. As Dr. Anja Kühne, a Berlin-based internist and vaccination advocate, noted in a recent interview with Deutsche Medizinische Wochenschrift, “We don’t wait for hypertension to cause a stroke before checking blood pressure. The same logic applies to vaccine-preventable diseases — prevention works best when it’s routine.”
stopping measles transmission depends on maintaining high population immunity. While children remain a focus of vaccination programs, adults are increasingly recognized as a critical piece of the puzzle. By making immunity verification a standard part of adult healthcare, clinics can help close dangerous gaps and prevent measles from regaining a foothold in places where it was once considered under control.
As of May 2024, national health agencies continue to monitor measles activity closely. The next official update on European measles surveillance is expected from the ECDC in June 2024, which will provide updated case counts and trend analysis. Readers are encouraged to consult their local public health authority or healthcare provider for personalized advice on vaccination status.
Have you checked your measles vaccination status recently? Share your experience or questions in the comments below, and consider sharing this article to help others stay informed.